Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanzalintinib + nivolumab
- Development stage
- Phase 3
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of **zanzalintinib** (a novel, potent, oral small molecule tyrosine kinase inhibitor targeting multiple receptors including MET, AXL, VEGF, and MER) and **nivolumab** (a monoclonal antibody immune checkpoint inhibitor of PD-1) is being investigated for the treatment of advanced or metastatic renal cell carcinoma (RCC)[1][3][5]. Zanzalintinib inhibits multiple pathways involved in tumor growth and angiogenesis, while nivolumab works by enhancing anti-tumor immunity through PD-1 blockade[1][3]. Clinical studies such as STELLAR-002 and STELLAR-304 report a promising overall response rate (63%) and manageable safety profile in untreated stage 4 RCC[1][3][5].
- Brand names
- XL092 + nivolumab
- Other names
- zanzalintinib plus nivolumabXL092 plus nivolumabXL-092 plus nivolumabXL 092 plus nivolumab
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)MERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on zanzalintinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanzalintinib + nivolumab.